Citations

Clear

4847 citation(s) found for "Tu, Eric".

Long-Term Prospective Quality-of-Life Outcomes in 445 Patients with Sporadic Vestibular Schwannoma
Carlson, Matthew L. , Babajanian, Eric E. , Lohse, Christine M. , Tombers, Nicole M. , Link, Michael J.

Mayo Clinic

Otology & Neurotology | October 23, 2024 | Volume: 45 | Issue: 10 | Pages: 1167-1171

10.1097/mao.0000000000004328 | PMID 39439048 Get It

Objective To evaluate the long-term changes in sporadic vestibular schwannoma (VS) disease-specific quality-of-life (QOL) outcomes. Study Design Prospective longitudinal study using the Penn Acoustic Neuroma Quality of Life (PANQOL) Scale. Setting National survey. Patients Patients with sporadic VS who completed a baseline survey before treatment and at least one follow-up survey recruited through the authors’ center and through the Acoustic Neuroma Association. Interventions Observation, microsurgery, radiosurgery. Main Outcome Measures Changes in PANQOL scores from baseline to most recent survey. Results Among 445 eligible patients the mean duration of follow-up was 4.4 (SD, 2.3) years, including 122, 218, and 105 in the observation, microsurgery, and radiosurgery groups, respectively. Patients managed with observation (p = 0.03) or microsurgery (p < 0.001) demonstrated improvement in anxiety scores. Changes in facial function scores differed significantly by management group (p = 0.01), with patients undergoing microsurgery demonstrating a mean decline of 10 points in facial function scores compared with mean declines of 3 for those managed with observation or radiosurgery. Hearing loss scores decreased similarly over time for all three groups (p = 0.3). There were minimal changes in total PANQOL scores over time across all management groups (p = 0.5). Conclusions Long-term changes in total QOL among VS management groups are not significantly different. Microsurgery may continue to confer an advantage regarding improvement in anxiety postoperatively, but with a greater decline in facial function when compared to observation or radiosurgery. Long-term declines in hearing loss scores were not statistically significantly different among groups.
P12.09.A EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
Hanft, Simon , Elder, B L, Giglio, Pierre , Wu, Siqi , Farrell, Christopher , Alnahhas, Iyad , Lee, I-Y., Walbert, Tobias , Boockvar, John A. , Aregawi, Dawit , Kim, L., Schulder, Michael , Singer, S, Correia, Carlos Eduardo Silva , Ramakrishna, Rohan , Jeyapalan, Suriya, Magge, Rajiv , Agarwal, Vijay , Amankulor, N, Quinones-Hinojosa, A, Neese, Laura L., Scott, Charles , Pérez‐Ollé, Raül, Andrews, David , Lee, Ian , Lee, Ian Y , Elder, B, Lee, I Y, Vojnic, Morana , Zacharia, Brad E. , Kim, L., Ghatan, Saadi , Wu, J, Patel, Nitesh V. , Bhatia, Ankush , Brennan, Cameron , Evans, L, Gill, B, Sengupta, Soma , Wong, Eric T. , Amankulor, N, Quinones-Hinojosa, A, Andrews, D

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v67-v68

10.1093/neuonc/noae144.222 Get It

Abstract BACKGROUND Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax has utilized its Goldspire™ platform to create IGV-001, an autologous biologic-device combination product for the treatment of newly diagnosed GBM (ndGBM). IGV-001 consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA (IMV-001), irradiated and administered via biodiffusion chambers implanted in the abdomen. Together, these components stimulate immunogenic cell death and antigen release. In a phase 1b study in patients with ndGBM, IGV-001 was well tolerated without unexpected adverse events. Multiple efficacy signals were also observed, including significant improvements in progression-free survival, overall survival, radiographic evidence of tumor response, and changes in immune response biomarkers. A phase 2b randomized, multicenter, double-blind, placebo-controlled study to assess the safety and efficacy of IGV-001 in patients with ndGBM (ClinicalTrials.gov identifier: NCT04485949) is ongoing. Here, we present the first safety data from the study. MATERIAL AND METHODS After surgical resection, patients are treated with IGV-001 or placebo followed by SOC. The study will enroll approximately 93 patients at 20 sites in the United States, with a 2:1 randomization favoring IGV-001. The primary outcome is progression-free survival, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include overall survival, defined as the time from randomization to death due to any cause, and safety. RESULTS As of February 2, 2024, a total of 72 patients have been randomized and 69 have been implanted with IGV-001 or placebo plus SOC. The median age was 60.0 years (range, 24-70 years). Most randomized patients (76.4%) were 51-70 years of age, and the male:female ratio was 2.27. A total of 39/45 (86.7%) patients with enough follow-up time, initiated treatment with concurrent radiation and temozolomide. A total of 9/72 (12.5%) randomized patients discontinued treatment, including 7 patients who discontinued during the SOC treatment period. No patients discontinued treatment for adverse events, protocol deviations, or death. A total of 11/72 (15.3%) randomized patients discontinued the study after randomization. CONCLUSION To date, the review of blinded safety data did not show any emerging risk and supports that there is no change to the benefit-risk profile of treatment with IGV-001 versus placebo. The data will be updated before presentation.
P27.18.A RADIOGRAPHIC AND CLINICAL RESPONSE OF SACRAL WHO GRADE 2 MYXOPAPILLARY EPENDYMOMA WITH PROTON BEAM RADIATION AND TEMOZOLOMIDE WITHOUT SURGICAL RESECTION
Valerius, Allison R. , Rose, Peter S. , Breen, William G. , Thomsen, Anna, Sener, Uğur , Lehrer, Eric J. , Baykal, D

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v141-v141

10.1093/neuonc/noae144.480 Get It

Abstract BACKGROUND Myxopapillary ependymomas (MPE) are slow-growing tumors of the spine typically involving the medullary conus and cauda equina. MPE is regularly managed with surgical resection with radiation therapy reserved for cases where gross total resection cannot be achieved. Management of inoperable cases represents a clinical challenge. No systemic therapy is approved for treatment of MPE. Addition of chemotherapy may improve outcomes for cases not amenable to resection. MATERIAL AND METHODS We report feasibility and preliminary efficacy of combination treatment with proton beam radiation therapy and temozolomide chemotherapy for a patient with large, unresectable MPE. RESULTS A 19-year-old female presented with one year of gradually worsening hip and back pain despite treatment with physical therapy. MRI Lumbar spine identified a destructive and expansile T2-heterogenous and hyperintense intraosseous mass (14 x 12 x 13 cm) with extraosseous expansion involving the sacrum, coccyx, and left SI joint with abnormal soft tissue enhancement extending along the posterior spine. No additional lesions were identified on neuro-axis imaging. Biopsy of the mass was consistent with a WHO grade 2 myxopapillary ependymoma. Standard treatment of care would include complete surgical resection. Unfortunately, this would require a morbid procedure in an en block fashion with immediate and permanent loss of bowel, bladder, sexual, and ambulatory function in a young patient whose primary symptom was pain and mild weakness. It was therefore elected to treat the patient in an unconventional approach and begin with proton beam radiation therapy (59.4 Gy in 33 fractions) with concurrent temozolomide followed by 6 cycles of adjuvant temozolomide. Mild clinical improvement and significant radiographic response were achieved (size reduced to 8 x 7 x 11 cm). CONCLUSION This case suggests a potential role for use of proton radiation therapy with concurrent and adjuvant temozolomide for management of myxopapillary ependymoma not amenable to surgical resection.
Stenosis of the glomerulotubular neck in progressive chronic kidney disease
Đenić, Aleksandar , Aperna, Fnu, Sharma, Vidit , Denic, Aleksandar , Cohen, Eric P. , Mullan, Aidan F. , Barisoni, Laura , Gibson, Ian W. , Rule, Andrew D.

Mayo Clinic

Nephrology Dialysis Transplantation | October 17, 2024 | Volume: 40 | Issue: 5 | Pages: 917-928

10.1093/ndt/gfae234 | PMID 39415419 Get It

ABSTRACT Background Morphology and morphometric evaluation of lesions beyond conventional parameters can inform the pathophysiology of chronic kidney disease (CKD). We sought to determine whether the occurrence of glomerulotubular neck stenoses associates with progressive CKD. Methods We evaluated the normal parenchyma from radical nephrectomies removed for tumor between 2000 and 2021 and analyzed cortex for stenoses of the glomerulotubular neck. Stenosis of the glomerulotubular neck is defined a focal narrowing for which the draining tubule has a greater diameter than at the neck. Progressive CKD was defined as dialysis, kidney transplantation, sustained estimated glomerular filtration rate (eGFR) &lt;10 mL/min/1.73 m2 or sustained 40% decline from the post-nephrectomy eGFR. Each case of progressive CKD was age- and sex-matched to two controls without progressive CKD. Logistic regression models assessed the risk of progressive CKD with stenotic necks adjusting for other histological features, kidney function and CKD risk factors. Results There were 65 cases with a mean of 255 glomeruli and 130 controls with a mean of 329 glomeruli. Among both cases and controls, 5% of glomeruli showed visible glomerulotubular necks. The proportion of necks that were stenotic was higher in cases than controls (35% vs 11%, P &lt; .0001). Stenotic necks associated with progressive CKD independent of other histologic and clinical characteristics. Conclusion Glomerulotubular neck stenosis is associated with development of progressive CKD.
Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity
Lyu, Yu-Xuan, Wilczok, Dominika , Antebi, Adam , Vojta, Aleksandar , Stolzing, Alexandra , Moskalev, Alexey , Georgievskaya, Anastasia , Maier, Andrea B. , Olsen, Andrea, Groth, Anja , Brunet, Anne , Jamil, Aisyah, Kulaga, Anton , Bhatti, A.R., Yaden, Benjamin C., Djordjevic, Boris, Chen, Chieh, Huang, Christine Yuan, Chen, Danica , Sołdacki, Dariusz, Meyer, David H. , Chini, Eduardo N. , Morgen, Eric , Vernet, Erik , Pinilla, Estefano, Mercken, Evi M. , Finger, Fabian , Kuipers, Folkert , Gyülvészi, Gábor, Zmudze, Garri, Blander, Gil , Pincus, Harold A., McClure, Joshua, Kirkland, James L. , Peyer, James , McLaughlin, Jerry L., Mannick, Joan B. , Betts-LaCroix, Joe , Sedivy, John M. , Speakman, John R. , Shlain, Jordan, Maltzahn, Julia von , Andreasson, Katrin I. , Moody, Kelsey , Fortney, Kristen , Niedernhofer, Laura J., Veenhoff, Liesbeth M. , Melton, Lisa , Quarta, Marco , Koval, Maria, Marinova, Maria B., Hamalainen, Mark, Unfried, Maximilian , Ringel, Michael S. , Filipović, Miloš R. , Topors, Mourad, Mitin, Natalia , Roy, N. N., Pintar, Nika, Barzilai, Nir , Binetti, Paolo, Kohlhaas, Paul, Rubin, Paul , Kamya, Petrina, Muñoz‐Cánoves, Pura , Конрад, Р. , Ripa, Roberto , Mansukhani, Robin, Büttner, Sabrina , Brunemeier, Sebastian, Jakimov, Sergey, Rosenzweig‐Lipson, Sharon, Tsai, Shih‐Yin , Rando, Thomas A. , Peterson, Timothy R. , Woods, Tina , Wyss‐Coray, Tony , Finkel, Toren , Strauss, Tzipora , Longo, Valter D. , Sorrentino, Vincenzo , Sebastiano, Vittorio , Li, Wenbin , Suh, Yousin , Niedernhofer, Laura J. , Lu, Yuxuan , Passos, Joao, Niedernhofer, Laura J , Wyss-Coray, Tony , Bakula, Daniela , Lyu, Yu-Xuan, Fu, Qiang , Ying, Kejun , King, Aaron, Olsen, Andrea, Simon, Anna Katharina , Jamil, Aisyah, Bhatti, Asif, Pedersen, Bente Klarlund , Schumacher, Björn , Kennedy, Brian Keith , Huang, Christine Yuan, Correll, Christoph Ulrich , Murphy, Coleen Tara , Ewald, Collin Y. , Valenzano, Dario Riccardo , Erritzøe, David , Sinclair, David , Teeling, Emma C. , Verdin, Eric , Pinilla, Estéfano , Fang, Evandro Fei , Bischof, Evelyne Y. , Pun, Frank W. , Civiletto, Gabriele , Justice, Jamie N. , Vijg, Jan , Gruhn, Jennifer R. , McLaughlin, Jerry, Passos, João F. , Baur, Joseph A. , Shlain, Jordan, Palikaras, Konstantinos , Rasmussen, Lene Juel , Ferrucci, Luigi , Koval, Maria, Topors, Mourad, Roy, Nawal, Pintar, Nika , Singh, Parminder Pal , Robbins, Paul D. , Fedichev, Peter O. , Cabo, Rafael de , Faragher, Richard , Konrad, Rob, Wickström, Sara A. , Brunemeier, Sebastian A., Luo, Shan , Dimmeler, Stefanie , Gladyshev, Vadim N. , Dwaraka, Varun B. , Gorbunova, Vera , Acosta-Rodríguez, Victoria A. , Suh, Yousin , Zhavoronkov, Alex , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | October 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.18632/aging.206135 | PMID 39418098 Get It

High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy
Han, Jianmin, Isom, Scott , Smith, Wesley, Begley, Stephanie, Jenneman, Dakota, Bose, Rupali, Seegars, Mary Beth, McCall, Chad M. , Hsi, Eric D. , Ghosh, Nilanjan

Mayo Clinic

Leukemia & Lymphoma | October 16, 2024 | Volume: 66 | Issue: 2 | Pages: 325-328

10.1080/10428194.2024.2414899 | PMID 39411845 Get It

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519

10.6004/jnccn.2024.0052 | PMID 39413835 Get It

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Patient-Level Value Analysis in Total Hip Arthroplasty: Optimizing the Value of Care Delivery
Doxey, Stephen A. , Huyke‐Hernández, Fernando A. , Davidson, S. Whately, Kleinsmith, Rebekah M. , Qian, Lily J. , Krohn, Eric , Horst, Patrick K. , Bingham, Joshua S. , Cunningham, Brian P. , Davidson, Samuel , Krohn, Eric J , Bingham, Joshua S

Mayo Clinic

Journal of Bone and Joint Surgery | October 15, 2024 | Volume: 106 | Issue: 24 | Pages: 2338-2346

10.2106/jbjs.24.00130 | PMID 39692715 Get It

Background: Value is defined as the ratio of patient outcomes to the cost of care. One method to assess value is through patient-level value analysis (PLVA). To our knowledge, this tool has not previously been implemented in the setting of total hip arthroplasty (THA). The purposes of this study were to perform PLVA for a 1-year episode of care among patients undergoing primary THA and to identify characteristics that affect value in a metropolitan health-care system. Methods: The patient-reported outcome (PRO) measure database of the institution was queried for all primary THAs from 2018 to 2019. The PRO measure that was utilized was the Hip disability and Osteoarthritis Outcome Score, Joint Replacement (HOOS-JR). Cost was evaluated with use of time-driven activity-based costing (TDABC) for a 1-year episode of care (consisting of the day of surgery, inpatient stay, discharge facility, postoperative appointments, and physical therapy). The primary outcome was the 1-year value quotient, or the ratio of the 1-year change in HOOS-JR to the cost of the episode of care (V HOOS ). The value quotient was compared among all included patients and evaluated for variables that may affect the overall value of the episode of care. Results: In total, 480 patients were included in the analysis. The mean improvement in the HOOS-JR was +34.9 ± 16.1 (95% confidence interval [CI]: 33.5, 36.3). The mean cost was $13,835 ± $3,471 (95% CI: $13,524, $14,146). The largest contributor to cost was implants (39.0%), followed by post-recovery care (i.e., inpatient stay and specialized nursing facilities; 24.1%). Change in the HOOS-JR was poorly correlated with the cost of care (r = −0.06; p = 0.19). THAs performed at an ambulatory surgery center (ASC) with discharge to home demonstrated higher value (V HOOS = 0.42) than THAs performed at a hospital with discharge to a rehabilitation facility (V HOOS = 0.15; analysis of variance F-test, p < 0.01). Conclusions: Our study found that PROs did not correlate with costs in the setting of primary THA. Implants were the largest cost driver. Surgical setting (an ASC versus a hospital) and discharge destination influenced value as well. PLVA is a value measurement tool that can be utilized to optimize components of the care delivery pathway. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Closing the gap between biology and classification in splenic B‐cell lymphomas
Blombery, Piers , Ferry, Judith A. , Ondrejka, Sarah L. , Seymour, John F. , Zamò, Alberto , Tzankov, Alexandar , Zamò, Alberto , Tzankov, Alexandar , Jong, Daphne de , Hsi, Eric D.

Mayo Clinic

Histopathology | October 15, 2024 | Volume: 86 | Issue: 1 | Pages: 69-78

10.1111/his.15323 | PMID 39403047 Get It

The mature splenic B‐cell lymphomas are an enigmatic group of lymphoid neoplasms that have long caused significant difficulty for the practicing pathologist due to overlapping diagnostic features among entities and the decreasing availability of splenic tissue for assessment. While some entities have highly characteristic and specific clinicopathological features (e.g. hairy cell leukaemia), others are substantially more difficult to recognise (e.g. splenic diffuse red pulp lymphoma). At the same time, classification systems have been evolving, resulting in multiple changes to the boundaries among these entities and even the existence of some entities in their own right. Moreover, unbiased multi‐omic interrogation (whole genome/transcriptome sequencing, methylome) of the splenic B‐cell lymphomas over the past decade has given us significant insights into the underling biology of these neoplasms. We present a clinicopathological perspective on the historical, current and future state of the diagnosis and classification of splenic B‐cell lymphomas integrating multi‐omic data and highlighting areas of focus for the field in order to continue to strive to improve patient outcomes through accurate diagnosis.
Incidence of revision surgery and patient-reported outcomes within 5 years of the index procedure for grade 1 spondylolisthesis: an analysis from the Quality Outcomes Database spondylolisthesis data
Birlingmair, Jacob, Djurasovic, Mladen, Mummaneni, Praveen V. , Asher, Anthony L. , Bisson, Erica F. , Bydon, Mohamad , Chan, Andrew K. , Chou, Dean , Coric, Domagoj , Foley, Kevin T. , Fu, Kai-Ming, Haid, Regis W., Knightly, John J. , Le, Vivian , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Slotkin, Jonathan R., Virk, Michael S. , Wang, Michael Y. , Glassman, Steven D. , Carreon, Leah Y. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.3171/2024.6.spine24488 | PMID 39393106 Get It

OBJECTIVE Some patients treated surgically for grade 1 spondylolisthesis require revision surgery. Outcomes after revision surgery are not well studied. The objective of this study was to determine how revision surgery impacts patient-reported outcomes (PROs) in patients undergoing decompression only or decompression and fusion (D+F) for grade 1 spondylolisthesis within 5 years of the index surgery. METHODS Patients in the 12 highest Quality Outcomes Database (QOD) enrolling sites with a diagnosis of grade 1 spondylolisthesis were identified and the incidence of revision surgery between the decompression-only and D+F patients were compared. PROs were compared between cohorts requiring revision surgery versus a single index procedure. RESULTS Of 608 patients enrolled, 409 had complete 5-year data available for this study. Eleven (13.3%) of 83 patients underwent revision in the decompression-only group as well as 32 (9.8%) of 326 in the D+F group. For the entire cohort, patients requiring revision had significantly worse PROs at 5 years: Oswestry Disability Index (ODI) 27.4 versus 19.4, p = 0.008; numeric rating scale for back pain (NRS-BP) 4.1 versus 3.0, p = 0.013; and NRS for leg pain (NRS-LP) 3.4 versus 2.1, p = 0.029. In the decompression-only group, the change in 5-year PROs was not impacted by revision status: ODI 31.9 versus 24.2, p = 0.287; NRS-BP 1.9 versus 2.9, p = 0.325; and NRS-LP 6.2 versus 3.7, p = 0.011. In the D+F group, the change in 5-year PROs was diminished if patients required revision: ODI 19.1 versus 29.1, p = 0.001; NRS-BP 3.0 versus 4.0, p = 0.170; and NRS-LP 2.3 versus 4.6, p = 0.001. CONCLUSIONS The most common reasons for reoperation within 5 years in the decompression-only group were repeat decompression and instability, whereas in the D+F group the most common reason was adjacent-segment disease. The need for revision resulted in modestly diminished benefit compared with patients with no revisions. These differences were greater in the fusion cohort compared with the decompression-only cohort. The mean PRO improvement still far exceeded minimal clinically important difference thresholds for all measures for patients who underwent a revision surgery.